Yinghua Du

Dr. Du has over 15 years of US industry experience in drug discovery and development, with a particular focus on biometabolism and bioanalytical (including GLP compliant, GCP clinical sample analysis). She has led and fully participated in two drug candidates for IND filings in the bioanalytical and DMPK areas, including the successful IND and NDA submissions for Sustiva (HIV drug), and the IND and clinical phase I and II DMPK studies for Pfizer’s anti-cancer drug Sutent-Sotan, and has deep expertise in mass spectrometry. Prior to joining Frontage, Dr. Du was the founder and CSO of Calibra, a technology company focused on clinical testing and clinical biomarker development and IVD kit manufacturing.
Dr. Du graduated from Brigham Young University, Provo, Utah, with a Ph.D in analytical chemistry (1991-1996). She has a patent (Alicia (Yinghua) Du, “Method of Neonatal Urine Screening for Organic Acid” U.S. Patent, US2010/ 0126254A1, May 27, 2010). 0126254A1, May 27, 2010, Mass Spectrometry of Organic Acids in Neonatal Urine) and more than 50 abstracts from journals and academic conferences. Contributed several chapters in two books on drug analysis and toxicology. He has taught several short courses on bioanalysis, especially at the China Mass Spectrometry Conference and at the ASMS Mass Spectrometry User Conference in the US. Dr. Du is one of the founding members of CBF (China Bioanalytical Forum) and has led and participated in the successful annual meetings in Beijing, Shanghai and Nanjing for several years.